Lentiviral vectors in human gene therapy: what is measured and what is still unclear about their integration
Journal of translational medicine · 2026
In plain language
This is a review of human gene therapies that use vectors derived from HIV-1. It is not about FeLV or cats. It describes how these vectors integrate into human cell DNA, and what is and is not yet understood about the consequences. Its link to FeLV is only indirect, by analogy.
Scientific detail
This is a narrative review published in 2026 on HIV-1-derived lentiviral vectors (LVVs) used in human gene therapy. The document does not mention FeLV or cats, and it reports no sample size.
According to the review, vector copy number (VCN), measured by quantitative PCR, is the current standard clinical measure of engraftment of LVV-modified cells, but it does not determine integration site location or clonality. This statement describes human clinical practice as reported in a review (evidence level D).
The authors identify as a knowledge gap that the effect of LVV integration on host RNA regulation and splicing, and its link to clinical outcomes and long-term vector safety, remains incompletely understood.
The review also describes integration-profiling methods, including the HIV SMRTcap long-read approach, that might be adapted to other retroviruses. The authors acknowledge limitations: current integration-site protocols sample sparsely, short-read NGS maps poorly in repetitive regions, LTR-based methods may miss proviruses with deletions, and clonal kinetics are not routinely measured. Relevance to FeLV is indirect and analogical (retroviral integration, insertional mutagenesis, clonal persistence of integrated cells); there are no feline data.
What we know
In human LVV therapies, vector copy number by quantitative PCR is the standard measure of engraftment, but it does not show where the vector integrated or whether cells derive from a single clone. Integration-profiling methods exist, but the authors acknowledge technical limitations.
What we don't know
It is not fully understood how LVV integration affects host RNA regulation and splicing, or how this relates to clinical outcomes and long-term safety. This document contains no evidence in cats or FeLV, and it is untested whether the methods described would work for FeLV.
Evidence
EvidenceLevel D — Indirect evidence: other species or retrovirusConfidence 85/100
Vector copy number, measured by quantitative PCR, is the current standard clinical measure of LVV-modified cell engraftment but does not determine integration site location or clonality.
Excerpt verified in the source — verbatim, in the source's own language“VCN is performed using quantitative polymerase chain reaction (PCR) [ 95 – 99 ] and does not determine integration site location or clonality [ 100 ].”
This describes human clinical practice for LVV therapies as reported in a review. It is not a feline finding and does not establish anything about FeLV.
Open questionConfidence 80/100
The effect of LVV integration on host RNA regulation and splicing, and its link to clinical outcomes and long-term vector safety, remains incompletely understood.
The authors identify this as a knowledge gap. Resolving it would need higher-resolution profiling methods, and it does not by itself bear on FeLV.
Provenance
Source: Adaptation of lentiviral vectors for viral gene therapy and their impact on host cell biology.
AVA